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Management of gastrointestinal toxicity 
from nivolumab therapy
ABSTRACT 
Nivolumab is a monoclonal antibody with immunomodulatory action blocking a PD-1 receptor (programmed 
death-1). This action causes T-cell activation against the neoplasm and all other body tissues. This can lead to 
many different autoimmune-regulated toxicities. The most common are gastrointestinal complications such as 
enterocolitis and hepatitis. These adverse events may be successfully treated if a diagnosis is quick and appropri-
ate. Such an approach may also enable continuation of nivolumab therapy in many patients.
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Introduction
Nivolumab is a modern antineoplastic drug which ac-
tually may be used in the immunotherapy of melanoma, 
non-small cell lung cancer, renal cancer, Hodgkin lym-
phoma, urothelial cancer and squamous cell head and 
neck cancer. There are some ongoing studies evaluating 
the efficacy of this agent in the gastrointestinal and liver 
cancers [1].
Nivolumab is a human monoclonal antibody be-
longing to a group of drugs, the anticancer effect of 
which results from their influence on the immunologi-
cal system. The mechanism of action of nivolumab is 
based on blocking the PD-1 receptor (programmed 
death-1). A blocked receptor cannot bind the PD-L1 
and PD-L2 ligands, molecules that are expressed on 
the neoplastic cells in order to inhibit the proliferation 
of lymphocytes T and to stop the secretion of the anti-
cancer cytokines. Inhibition of the interaction between 
the PD-1 receptor and its PD-L1 and PD-L2 ligands 
by nivolumab have the opposite result — an increased 
anticancer activity of lymphocytes T [2].
Nivolumab and the other drugs with a similar im-
munomodulatory effect (ipilimumab, pembrolizumab, 
atezolizumab, etc.) influence each tissue, not only the 
neoplastic one. For this reason, the use of these agents 
involves a risk of autoimmunological complications 
(immune-related adverse events — irAEs) [3, 4]. In the 
case of nivolumab, the most common manifestations of 
the adverse events are: weakness, rush, diarrhoea, consti-
pation, skin itching, and joints pains. The majority of these 
side effects results from dermatitis, enterocolitis, arthritis, 
or hepatitis with an immunologic background [5].
The data concerning the toxicity of nivolumab and 
other PD-1 inhibitors are based on just a few papers. The 
majority of information concerning the adverse effects 
of immunotherapy derives from the clinical studies of 
ipilimumab, the mechanism of action of which is slightly 
different but still similar to nivolumab. The adverse 
events of nivolumab seem to be less frequent and of 
lower grade [6–8].
The most common toxicities concerning the gastroin-
testinal tract are enterocolitis and hepatitis. A few cases 
of esophagitis and pancreatitis have been also reported.
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Enterocolitis
Diarrhoea is observed in about one third of patients 
undergoing immunotherapy. It usually occurs in the 
third month of therapy [9]. Diarrhoea may have an 
infectious — fungal, bacterial, or viral — as well as au-
toimmunological background. About 8–22% of patients 
receiving immunotherapy develop autoimmunological 
enterocolitis [10]. The autoimmunological inflammation 
may lead to a potentially severe damage and perfora-
tion of the bowel in 1–1.5% and can be fatal in 1.1% 
of patients receiving ipilimumab [10–12]. Data coming 
directly from the clinical studies of nivolumab suggest 
that the clinically severe form of the diarrhoea [Common 
Terminology Adverse Events (CTAE) grade 3 and 4] 
occurs less frequently than post ipilimumab, i.e. in 1–2% 
of patients [13, 14]. 
The aetiology of the diarrhoea may be different, 
which is why it always requires rapid diagnosis. Early 
determination of the cause of diarrhoea enables an 
effective treatment [15]. The initial phase of diagnos-
tics includes tests that exclude infectious background 
— a stool mycology and parasite analysis should be per-
formed as well as testing for the presence of Clostridium 
difficile toxin. Moreover, blood should be tested for 
cytomegalovirus (CMV) infection. Exclusion of the 
infectious background suggests an autoimmunological 
aetiology of the diarrhoea [10]. Coexistence of such 
symptoms as: ulcerations of the oral cavity, perianal 
changes (ulcers, fissures, fistulas), arthritis, skin changes, 
liver damage, or endocrinopathies additionally confirms 
an autoimmunological background [16]. The laboratory 
tests may reveal anaemia, elevated acute phase protein 
(AFP), and hypoalbuminaemia [16]. 
A definitive diagnosis of unspecific enterocolitis 
must be based on the endoscopic and histopathological 
evaluation. In the majority of patients, immunother-
apy-induced enterocolitis involves rectum and/or the 
left part of the colon. That is why fibrosigmoidoscopy 
should be done as a first exam (this technique permits 
evaluation of the rectum and the left part of the colon). 
If the result is normal, a colonoscopy should be per-
formed because in some patients, changes involve only 
the proximal part of the colon [16]. Endoscopy reveals 
inflammation manifested by the absence of the vascular 
pattern, petechiae, redness, and oedema of the mucosa 
as well as erosions and ulcerations [16, 17]. Histopatho-
logical tests (or eventually immunohistochemical ones) 
exclude infectious background and permit confirmation 
of non-specific enterocolitis. Microscopic evaluation of 
the damage induced by ipilimumab reveals a different 
type of histopathological change than those observed 
in Crohn’s disease or in ulcerative enterocolitis [16]. By 
contrast, changes induced by nivolumab are described 
as similar to the ones observed in ulcerative enterocol-
itis. These findings may have therapeutic implications 
such as inclusion of 5-aminosalcylic acid into treatment 
of this complication [18]. 
Diet is a first therapeutic intervention, notwithstand-
ing the cause and grade of symptoms. The major aim 
of the diet is to slow the peristalsis of the bowels and to 
decrease the enteric secretion. For this reason, a patient 
should not consume any raw vegetables or fruit that 
contain pectins (agents that boost peristalsis). Higher 
amounts of pectins are included in apples, apricots, 
cherries, carrots, oranges, bananas, and citrus peel. 
Patients with diarrhoea should also avoid any preserve 
containing enumerated fruit, e.g. jams, because they 
also contain pectins. Another group of food and drinks 
that should not be consumed in case of diarrhoea are: 
soya, oats, corn, sweets, and aerated drinks because they 
contain fructose and sorbitol. All these products increase 
the volume of the stool [10, 19, 20]. If the diarrhoea 
is severe and watery, it may lead to dehydration and 
electrolyte imbalance. In this case, preferentially, oral 
rehydration and common multi-electrolyte formulations 
should be administered. In the mild form of diarrhoea 
(CTAC grade 1) nivolumab must not be stopped. The 
symptomatic therapy includes antidiarrhoeal drugs e.g. 
loperamide or atropine sulphate [1, 10]. 
If the abovementioned measures are not effective 
and autoimmunological enterocolitis is diagnosed 
or highly probable (infection has been excluded), or 
when the symptoms are severe, immunotherapy must 
be interrupted and glucocorticosteroids should be ad-
ditionally started. In the case of moderate symptoms 
(CTAE grade 2), therapy may include budesonide in 
dose of 9 mg per day for eight weeks [21]. If this drug 
is not effective, or if the symptoms are intense, clas-
sic glucocorticosteroids in a dose corresponding to 
0.5–1.0 mg/kg of prednisolone should be started imme-
diately. No effect of orally administered glucocorticos-
teroids or development of severe enterocolitis (CTAE 
grade 3 and 4) constitute an indication for therapy with 
intravenous methylprednisolone in dose of 1–2 mg/kg 
for five days. After this period oral glucocorticosteroids 
in a dose reduced by 4 mg of methylprednisolone every 
seven days should be started [10]. Corticotherapy in 
patients with nivolumab-induced enterocolitis is highly 
effective, reaching 87.5% [22]. Nonetheless, there is 
a group of patients resistant to this therapy. If after five 
days of intravenous steroid therapy no improvement is 
observed, intravenous infusion of infliximab in a dose 
of 5 mg/kg should be administered. Almost all patients 
respond very well to a single dose of infliximab [10, 11, 
16, 23]. Only in some rare cases another dose must be 
given two weeks after the first administration. A second 
indication for infliximab therapy is a reoccurrence of 
enterocolitis during the reduction of the dose of gluco-
corticosteroids [17, 18]. Some single studies suggest that 
vedolizumab may be an effective drug in the case of the 
steroid-resistant, nivolumab-induced enterocolitis [24]. 
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Table 1. Management of nivolumab-induced enterocolitis depending on the severity of symptoms according to the CTAE scale [1]
Grade (G1)
Up to 3 loose stools per day — continue nivolumab therapy — diet, antidiarrhoeal drugs
Grade 2 (G2) 
4–6 loose stools per day, alternatively blood present in a stool, general symptoms — stop nivolumab — budesonide or prednisone
Grade 3/4 (G3/G4)
> 6 loose stools per day, alternatively blood present in a stool, general symptoms, deficiencies — stop nivolumab — steroids 
intravenously, alternatively infliximab
Pharmacotherapy of nivolumab-induced enterocolitis is 
very rarely non-effective. In such circumstances, when 
a severe, life-threatening enterocolitis develops, which 
may result in perforation of the intestine, colectomy 
and ileostomy should be performed [16]. There are no 
confirmed data concerning the problem of restarting 
the immunotherapy after successful management of the 
enterocolitis. In patients with moderate enterocolitis 
(CTAE grade 2 and 3) who did not require therapy 
with infliximab, another attempt of nivolumab therapy 
seems acceptable. There is also a consensus concern-
ing a definitive end of immunotherapy in patients who 
developed a severe form of enterocolitis and required 
therapy with infliximab [1, 10].
The principles of management of enterocolitis de-
pending on its CTAE grade are presented in Table 1. 
Hepatitis
Nivolumab and other anti-PD-1 drugs may also 
induce hepatitis. This complication may occur at any 
period of the therapy, but usually it appears between 
the 6th and 12th week of treatment. Hepatitis concerns 
1–5% of patients [3, 25]. 
Clinical symptoms of hepatitis develop late and are 
related to a sever impairment of the liver. That is why 
the function of the liver should be monitored prior to 
and during the therapy, in order to detect as early as 
possible the impairment of this organ. The essential tests 
includes evaluation of the aminotransferases, gamma 
glutamyl transferase, alkaline phosphatase, and total 
bilirubin activity. 
The occurrence of the laboratory features of liver 
impairment during the pharmacotherapy is strong proof 
of its drug-induced aetiology. However, exclusion of all 
other common factors of liver impairment, e.g.: alcohol 
abuse, infection with hepatotropic viruses, or specific for 
immunotherapy — CMV infection, is always obligatory. 
In order to confirm the immunological background of 
the liver damage, evaluation of the presence of antinu-
clear antibodies as well as anti-smooth muscle antibodies 
should be done. Imaging exams (ultrasonography, com-
puted tomography) may be helpful but are inconclusive 
in diagnosing the immunological cause of liver impair-
ment. Liver biopsy is not necessary. It may be useful in 
uncertain cases or in cases with a fulminant course [26].
If a liver impairment is detected, the control evalu-
ation of liver function should be repeated at least once 
a week [1]. Persistence of the abnormal aminotrans-
ferase’s or total bilirubin level even in a low grade 
(aminotransferases 3–5 × normal value, CTAE grade 
2) constitutes an indication to stop the immunotherapy 
and to start the therapy with glucocorticosteroids (pred-
nisolone) in a dose corresponding to 1–2 mg/kg of body 
weight per day [27]. If this therapy is not effective or the 
symptoms are reoccurring during the reduction of the 
drug dose it is recommended to start again prednisolone 
at the dose of 2 mg/kg of body weight. Hepatitis usually 
resolves in 4–6 weeks of appropriate therapy and then 
the immunotherapy may be reassumed [1]. There are 
some recent data suggesting some benefits of adding 
ursodeoxycholic acid to the glucocorticosteroids. How-
ever, it is too early to recommend a common use of this 
drug in all patients [28]. 
Nivolumab must be definitively stopped in the case 
of occurrence of acute, expansive liver impairment (very 
high levels of aminotransferases — CTAE grade 3) or 
the appearance of symptoms of liver insufficiency (incl. 
increasing hyperbilirubinaemia — CTAE grade 3). In 
this situation, besides stopping the drug, intravenous 
glucocorticotherapy and N-acetylcysteine administra-
tion in dose of 1200 mg should be started [28]. No 
improvement when on this treatment constitutes an in-
dication to administer a mycophenolate mofetil in dose 
of 1000 mg [4, 29–31]. Unlike the other complications 
of immunotherapy, in hepatitis, the use of infliximab is 
not recommended, due to its hepatotoxicity. 
The principles of management of hepatitis, depend-
ing on its CTAE grade, are presented in Table 2.
Beside pharmacotherapy, in the case of liver impair-
ment an adequate diet based on fresh and healthy food 
has a supporting effect. It is recommended that light 
food products are used. The intake of dietary fat should 
be limited. The fat should be vegetable, e.g. rapeseed oil, 
sunflower oil, soybean oil, or olive oil. It is also advised 
that cooked, baked, or steamed products be consumed. 
Eating fried dishes is contraindicated [32].
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Table 2. Management of nivolumab-induced hepatitis depending on the severity of symptoms according to the CTAE scale [1]
Grade 1 (G1)
Aminotransferases < 3 × normal value — continue nivolumab — diet and control of aminotransferases level every 7 days
Grade 2 (G2)
Aminotransferases 3–5 × normal value — stop nivolumab — diet and control of aminotransferases level twice per week — no 
improvement start prednisone orally 
Grade 3 (G3)
Aminotransferases 5–20 × normal value and/or symptoms of liver insufficiency — stop nivolumab permanently — diet and 
methylprednisolone intravenously, if no improvement administer mycophenolate mofetil
Grade 4 (G4)
Aminotransferases > 20 × normal value- stop nivolumab permanently — diet and methylprednisolone intravenously — if no 
improvement, administer mycophenolate
Other complications of the 
gastrointestinal tract 
A few cases of oesophagitis induced by nivolumab 
immunotherapy have recently been reported. It usu-
ally manifested as dysphagia — gastroscopy-detected 
macroscopic features of oesophagitis, and the micro-
scopic evaluation revealed intraepithelial lymphocyte 
infiltrations. Glucocorticosteroids in doses similar to 
the therapy of enterocolitis constituted an effective 
treatment [33]. During immunotherapy with nivolumab 
pancreatitis may also occur. All data suggest that its 
course is asymptomatic and it is manifested by elevated 
serum levels of amylase and lipase [34]. This condition 
does not require any significant medical management. 
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